Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antihypertensive Drugs: Thiazide-Class Diuretics

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of left ventricular structural and functional abnormalities with aortic and brachial blood pressure variability in hypertensive patients: the SAFAR study.

Journal of human hypertension·2017

Same author

Clinical interaction between diabetes duration and aortic stiffness in type 2 diabetes mellitus.

Journal of human hypertension·2016

Same author

Erratum to: Thiazide-like/calcium channel blocker agents: a major combination for hypertension management.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2015

Same author

Association of left ventricular diastolic dysfunction with 24-h aortic ambulatory blood pressure: the SAFAR study.

Journal of human hypertension·2014

Same author

Thiazide-like/calcium channel blocker agents: a major combination for hypertension management.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2014

Same author

Pulse wave analysis with two tonometric devices: a comparison study.

Physiological measurement·2014

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Rilmenidine: a novel antihypertensive agent.

¹Department of Internal Medicine, Hôpital Broussais, Paris, France.

The American Journal of Medicine

|September 18, 1989

Summary

Rilmenidine, a novel antihypertensive agent, shows reduced central effects compared to other alpha 2-agonists. This dissociation offers a potentially safer therapeutic option for managing high blood pressure.

Area of Science:

Pharmacology
Cardiovascular Medicine
Neuroscience

Background:

Rilmenidine is a novel antihypertensive agent.
It is related to alpha 2-agonists, a class of drugs used to lower blood pressure.
Existing alpha 2-agonists like clonidine can cause significant central nervous system side effects such as sedation.

Purpose of the Study:

To describe the pharmacologic and clinical data of rilmenidine.
To evaluate its efficacy, acceptability, and effects on physiologic functions.
To hypothesize its mechanism of action and compare it to related drugs.

Main Methods:

Review of fundamental pharmacology studies.
Analysis of clinical pharmacology data.
Evaluation of therapeutic outcomes and patient acceptability.

More Related Videos

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Main Results:

Rilmenidine demonstrates a dissociation between antihypertensive and central effects at therapeutic doses.
This distinguishes it from clonidine and related alpha 2-agonists.
Potential mechanisms involve unknown properties counteracting sedation or contributions from imidazoline receptors.

Conclusions:

Rilmenidine presents a unique profile among antihypertensive agents.
Its reduced central effects may offer an improved safety profile.
Further research into its mechanism, including imidazoline receptor involvement, is warranted.